Bristol Myers Squibb Reports Phase 2b Data for Lecanemab in Hypertension

Bristol Myers Squibb today announced Phase 2b results for lecanemab in patients with hypertension. The study demonstrated that lecanemab improves quality of life compared to standard of care or placebo. These results provide important insights into the treatment of hypertension and support the continued development of lecanemab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.